2014

Actinium Pharmaceuticals Announces Additional Clinical Data From Multicenter Phase 1/2 Trial on Actinium's Actimab-A to Be Presented at American Society of Hematology Annual Meeting Initial Data Show That Fractionated Doses of Actimab-A in Combination with LDAC are Safe and Have Antileukemic Activity in Older Patients with Acute Myeloid Leukemia

NEW YORK, Dec. 2, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, reported today that data from an abstract of a study investigating the Company's pipeline hematology product Actimab-A will be presented at the American Society of Hematology's (ASH) 55th Annual Meeting and Exposition in New Orleans (December 5-10, 2013). The abstract includes summary of data from the study in acute myeloid leukemia (AML).

Abstract presented at this year's ASH meeting will report the initial data from the study demonstrating that administration of Actimab-A (monoclonal antibody HuM195 labeled with actinium 225) in fractionated doses is feasible, safe and has antileukemic activity.

An abstract summarizing the data is published on the ASH website at (https://ash.confex.com/ash/2013/webprogram/Paper63558.html)

Abstract Information

The Actimab-A abstract information is as follows:

Session: 615. Acute Myeloid Leukemia: Therapy, excluding Transplantation: Poster I

Abstract #1460:  "Phase I Trial Of The Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) In Combination With Low-Dose Cytarabine (LDAC) For Older Patients With Untreated Acute Myeloid Leukemia (AML)"

Date: Saturday, December 7, 2013

Time: 5:30 PM - 7:30 PM

Location: Ernest N. Morial Convention Center, Hall E

About Actimab-A™

Actimab-A is a drug candidate construct made using Actinium Pharmaceuticals' proprietary patented technology for arming monoclonal antibodies with alpha emitters actinium 225 and bismuth 213.  Antibodies are used as high precision delivery systems that bring powerful alpha emitters into or immediately next to targeted cancer cells.  Actimab-A consists of the Lintuzumab monoclonal antibody and actinium 225.

Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed.  The technology was first developed by Dr. David Scheinberg at Memorial Sloan Kettering Cancer Center. 

Lintuzumab is a monoclonal antibody that targets CD33, found on myeloid leukemia cells. It is the humanized version of M195, the antibody initially developed by Dr. David Scheinberg of Memorial Sloan Kettering Cancer Center.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB), is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers.  Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium-225 and bismuth-213 radiopharmaceuticals in conjunction with monoclonal antibodies.  The Company also develops other radiopharmaceuticals for select applications.

For more information:

Visit our web site www.actiniumpharmaceuticals.com

Contacts:

Media: 
Dennis S. Dobson Jr.  
Tel: (203) 258-0159  
Email: dennisdobsonjr@dobsonmediagroup.com  

Actinium Pharmaceuticals, Inc. 
Investor/Media Relations: Corey Sohmer, (646) 459-4201 
Email: csohmer@actiniumpharmaceuticals.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE Actinium Pharmaceuticals, Inc.



RELATED LINKS
http://www.actiniumpharmaceuticals.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.